Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice

Citations Over TimeTop 10% of 2016 papers

Abstract

Activation of the AKT/mTOR cascade and overexpression of c-Met have been implicated in the development of human hepatocellular carcinoma (HCC). To elucidate the functional crosstalk between the two pathways, we generated a model characterized by the combined expression of activated AKT and c-Met in the mouse liver. Co-expression of AKT and c-Met triggered rapid liver tumor development and mice required to be euthanized within 8 weeks after hydrodynamic injection. At the molecular level, liver tumors induced by AKT/c-Met display activation of AKT/mTOR and Ras/MAPK cascades as well as increased lipogenesis and glycolysis. Since a remarkable lipogenic phenotype characterizes liver lesions from AKT/c-Met mice, we determined the requirement of lipogenesis in AKT/c-Met driven hepatocarcinogenesis using conditional Fatty Acid Synthase (FASN) knockout mice. Of note, hepatocarcinogenesis induced by AKT/c-Met was fully inhibited by FASN ablation. In human HCC samples, coordinated expression of FASN, activated AKT, and c-Met proteins was detected in a subgroup of biologically aggressive tumors. Altogether, our study demonstrates that co-activation of AKT and c-Met induces HCC development that depends on the mTORC1/FASN pathway. Suppression of mTORC1 and/or FASN might be highly detrimental for the growth of human HCC subsets characterized by concomitant induction of the AKT and c-Met cascades.

Related Papers

• → Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy(2011)416 cited
• → Fatty Acid Synthase Activity in Tumor Cells(2008)41 cited
• → Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice(2015)2 cited
• → Abstract 1880: Role of fatty acid synthase and do novo lipogenesis in liver cancer development in mice.(2013)
• TARGETING LIPOGENESIS IN RETINOBLASTOMA: EVALUATION OF CHEMICAL INHIBITORS OF FATTY ACID SYNTHASE (FASN) AS ANTI-CANCER AGENTS(2012)